Outset Medical Names First Chief Nursing Officer
Outset Medical (Nasdaq: OM) has appointed Brittni McGill as its first Chief Nursing Officer, marking a significant addition to its executive team. McGill brings 18 years of nursing and hospital executive experience, previously managing over 1,400 employees at a 350-bed hospital.
In her prior role, McGill demonstrated notable success implementing Outset's Tablo system, achieving a 98% successful treatment rate and reducing central line blood stream infections by 75%. As CNO, she will lead clinical education and support programs for the dialysis nursing community, focusing on strategic outreach and clinical program innovation.
Outset Medical (Nasdaq: OM) ha nominato Brittni McGill come suo primo Chief Nursing Officer, rappresentando un'importante integrazione nel team esecutivo. McGill vanta 18 anni di esperienza nel settore infermieristico e nella gestione ospedaliera, avendo precedentemente diretto oltre 1.400 dipendenti in un ospedale con 350 posti letto.
Nel suo ruolo precedente, McGill ha ottenuto risultati significativi nell'implementazione del sistema Tablo di Outset, raggiungendo un tasso di successo del trattamento del 98% e riducendo le infezioni del flusso sanguigno da catetere centrale del 75%. Come CNO, guiderà i programmi di formazione clinica e di supporto per la comunità infermieristica di dialisi, concentrandosi su iniziative strategiche e innovazioni nei programmi clinici.
Outset Medical (Nasdaq: OM) ha designado a Brittni McGill como su primera Chief Nursing Officer, marcando una incorporación significativa a su equipo ejecutivo. McGill aporta 18 años de experiencia en enfermería y gestión hospitalaria, habiendo dirigido anteriormente a más de 1,400 empleados en un hospital de 350 camas.
En su rol anterior, McGill demostró un notable éxito implementando el sistema Tablo de Outset, logrando una tasa de éxito en tratamientos del 98% y reduciendo las infecciones del torrente sanguíneo por catéter central en un 75%. Como CNO, liderará programas de educación clínica y apoyo para la comunidad de enfermería de diálisis, enfocándose en la divulgación estratégica y la innovación de programas clínicos.
Outset Medical (나스닥: OM)은 브리트니 맥길을 첫 번째 최고 간호 책임자(CNO)로 임명하며 경영진 팀에 중요한 인재를 추가했습니다. 맥길은 18년간의 간호 및 병원 경영 경험을 보유하고 있으며, 이전에는 350병상 병원에서 1,400명 이상의 직원을 관리했습니다.
이전 직무에서 맥길은 Outset의 Tablo 시스템 도입에 성공하여 98%의 치료 성공률을 달성하고 중심정맥관 혈류 감염을 75% 감소시키는 성과를 보였습니다. CNO로서 그녀는 투석 간호 커뮤니티를 위한 임상 교육 및 지원 프로그램을 주도하며, 전략적 홍보와 임상 프로그램 혁신에 집중할 예정입니다.
Outset Medical (Nasdaq : OM) a nommé Brittni McGill comme sa première Chief Nursing Officer, marquant une importante addition à son équipe de direction. McGill apporte 18 ans d'expérience en soins infirmiers et en gestion hospitalière, ayant auparavant supervisé plus de 1 400 employés dans un hôpital de 350 lits.
Dans son rôle précédent, McGill a obtenu un succès notable en mettant en œuvre le système Tablo d'Outset, atteignant un taux de réussite des traitements de 98 % et réduisant les infections du sang liées aux cathéters centraux de 75 %. En tant que CNO, elle dirigera les programmes de formation clinique et de soutien pour la communauté infirmière en dialyse, en se concentrant sur la sensibilisation stratégique et l'innovation des programmes cliniques.
Outset Medical (Nasdaq: OM) hat Brittni McGill als erste Chief Nursing Officer ernannt, was eine bedeutende Verstärkung des Führungsteams darstellt. McGill bringt 18 Jahre Erfahrung in der Krankenpflege und Krankenhausleitung mit und leitete zuvor über 1.400 Mitarbeiter in einem Krankenhaus mit 350 Betten.
In ihrer vorherigen Position erzielte McGill bemerkenswerte Erfolge bei der Implementierung des Tablo-Systems von Outset, mit einer Erfolgsrate von 98 % bei Behandlungen und einer Reduzierung der zentralvenösen Blutstrominfektionen um 75 %. Als CNO wird sie klinische Bildungs- und Unterstützungsprogramme für die Dialysepflegegemeinschaft leiten, mit Fokus auf strategische Öffentlichkeitsarbeit und Innovationen in klinischen Programmen.
- Appointment of experienced executive with 18 years of nursing and hospital leadership
- Proven track record with Tablo implementation, achieving 98% treatment success rate
- Demonstrated ability to reduce central line infections by 75% in previous role
- Strategic focus on expanding clinical education and support programs
- None.
Accomplished nursing executive to lead Outset’s clinical education and support programs for the dialysis nursing community
SAN JOSE, Calif., July 30, 2025 (GLOBE NEWSWIRE) -- Outset Medical, Inc. (Nasdaq: OM) (“Outset”), a medical technology company pioneering a first-of-its-kind technology to reduce the cost and complexity of dialysis, today announced Brittni McGill has been named to the newly created role of Chief Nursing Officer where she will apply her extensive nurse executive leadership experience to help increase strategic outreach and clinical program innovation designed to empower nurses and nurse leaders and elevate care.
“Our entire Outset team understands and celebrates the critical role the nursing community and specifically, nurse executives, play in ensuring successful patient outcomes across the healthcare spectrum, particularly in dialysis,” said Dr. Michael Aragon, Chief Medical Officer. “Brittni is a forward-thinking, creative and results-driven nurse executive who brings deep expertise in driving cost effective, quality driven clinical transformation that we believe will bring immense value to the dialysis community.”
Mrs. McGill joins Outset following a distinguished 18-year nursing and hospital executive career, where she led acute care clinical services for a 350-bed hospital, managed more than 1,400 employees and developed and accredited multiple service lines and clinical programs. Her work in dialysis included leading the hospital’s change from an outsourced to an insourced dialysis service line using Tablo, which resulted in increasing the successful treatment rate to
“The Outset team has distinguished itself through a clear focus on improving the lives of dialysis patients throughout the care continuum while improving cost and efficiency for healthcare providers,” said Mrs. McGill. “I am excited to help advance such an essential moral mission.”
Mrs. McGill is a Doctorate of Nursing Practice candidate at Baylor University, and earned her M.S. in Nursing Administration from the University of Texas at Arlington and B.S. in Nursing from the University of Oklahoma. She has won numerous leadership awards and is affiliated with several professional organizations, including the American College of Healthcare Executives and the American Nurses Association.
About Outset Medical, Inc.
Outset is a medical technology company pioneering a first-of-its-kind technology to reduce the cost and complexity of dialysis. The Tablo® Hemodialysis System, FDA cleared for use from the hospital to the home, represents a significant technological advancement that transforms the dialysis experience for patients and operationally simplifies it for providers. Tablo serves as a single enterprise solution that can be utilized across the continuum of care, allowing dialysis to be delivered anytime, anywhere and by anyone. The integration of water purification and on-demand dialysate production enables Tablo to serve as a dialysis clinic on wheels, with 2-way wireless data transmission and a proprietary data analytics platform powering a new holistic approach to dialysis care. Tablo is a registered trademark of Outset Medical, Inc.
INDICATIONS FOR USE:
The Tablo® Hemodialysis System and TabloCart™ is indicated for use in patients with acute and/or chronic renal failure, with or without ultrafiltration, in an acute or chronic care facility. Treatments must be administered under physician’s prescription and observed by a trained individual who is considered competent in the use of the device. The Tablo Hemodialysis System is also indicated for use in the home. Treatment types available include Intermittent Hemodialysis (IHD), Sustained Low Efficiency Dialysis (SLED/ SLEDD), Prolonged Intermittent Renal Replacement Therapy (PIRRT), and Isolated Ultrafiltration.
This device is not indicated for continuous renal replacement therapy (CRRT) and is cleared for use for up to 24 hours. The dialysate generated by this device is not sterile and should not be used for intravenous (IV) infusion.
Contact
Jennifer Sipple
media@outsetmedical.com
FAQ
Who is the new Chief Nursing Officer at Outset Medical (OM)?
What are Brittni McGill's credentials and experience before joining Outset Medical?
What results did Brittni McGill achieve with Tablo in her previous role?
What will be Brittni McGill's responsibilities as Outset Medical's CNO?
